Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Delcath Systems, Inc. - Common Stock (NQ:DCTH)

9.370 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1
Open 9.370
Bid (Size) 9.300 (100)
Ask (Size) 10.50 (300)
Prev. Close 9.370
Today's Range 9.370 - 9.370
52wk Range 8.120 - 18.23
Shares Outstanding 7,906,728
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Delcath Systems, Inc.
Via Business Wire

Performance

YTD
-5.8%
-5.8%
1 Month
-9.4%
-9.4%
3 Month
+9.2%
+9.2%
6 Month
-10.8%
-10.8%
1 Year
-41.6%
-41.6%

More News

Read More
News headline image
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
From Delcath Systems, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For August 6, 2025 ↗
Via Benzinga
News headline image
Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Participate in Upcoming Investor Conferences
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Inc (NASDAQ:DCTH) Reports Q3 2025 Revenue Miss, Meets EPS Estimates ↗
Via Chartmill
News headline image
Delcath Systems Reports Third Quarter 2025 Results and Business Highlights
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Host Third Quarter 2025 Earnings Call
From Delcath Systems, Inc.
Via Business Wire
News headline image
Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Participate in Upcoming Investor Conferences
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath (DCTH) Q2 Revenue Jumps 210% ↗
Via The Motley Fool
News headline image
Delcath Systems Reports Second Quarter 2025 Results and Business Highlights
From Delcath Systems, Inc.
Via Business Wire
News headline image
Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference
From Delcath Systems, Inc.
Via Business Wire

Frequently Asked Questions

Is Delcath Systems, Inc. - Common Stock publicly traded?
Yes, Delcath Systems, Inc. - Common Stock is publicly traded.
What exchange does Delcath Systems, Inc. - Common Stock trade on?
Delcath Systems, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Delcath Systems, Inc. - Common Stock?
The ticker symbol for Delcath Systems, Inc. - Common Stock is DCTH on the Nasdaq Stock Market
What is the current price of Delcath Systems, Inc. - Common Stock?
The current price of Delcath Systems, Inc. - Common Stock is 9.370
When was Delcath Systems, Inc. - Common Stock last traded?
The last trade of Delcath Systems, Inc. - Common Stock was at 02/06/26 04:00 PM ET
What is the market capitalization of Delcath Systems, Inc. - Common Stock?
The market capitalization of Delcath Systems, Inc. - Common Stock is 74.09M
How many shares of Delcath Systems, Inc. - Common Stock are outstanding?
Delcath Systems, Inc. - Common Stock has 74M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.